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Abstract
Objective To determine whether dietary n-3 long chain polyunsaturated
fatty acid (LCPUFA) supplementation of pregnant women with a fetus
at high risk of allergic disease reduces immunoglobulin E associated
eczema or food allergy at 1 year of age.
Design Follow-up of infants at high hereditary risk of allergic disease in
the Docosahexaenoic Acid to Optimise Mother Infant Outcome (DOMInO)
randomised controlled trial.
Setting Adelaide, South Australia.
Participants 706 infants at high hereditary risk of developing allergic
disease whose mothers were participating in the DOMInO trial.
Interventions The intervention group (n=368) was randomly allocated
to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily) from
21 weeks’ gestation until birth; the control group (n=338) received
matched vegetable oil capsules without n-3 LCPUFA.
Main outcome measure Immunoglobulin E associated allergic disease
(eczema or food allergy with sensitisation) at 1 year of age.
Results No differences were seen in the overall percentage of infants
with immunoglobulin E associated allergic disease between the n-3
LCPUFA and control groups (32/368 (9%) v 43/338 (13%); unadjusted
relative risk 0.68, 95% confidence interval 0.43 to 1.05, P=0.08; adjusted
relative risk 0.70, 0.45 to 1.09, P=0.12), although the percentage of
infants diagnosed as having atopic eczema (that is, eczema with
associated sensitisation) was lower in the n-3 LCPUFA group (26/368
(7%) v 39/338 (12%); unadjusted relative risk 0.61, 0.38 to 0.98, P=0.04;
adjusted relative risk 0.64, 0.40 to 1.02, P=0.06). Fewer infants were
sensitised to egg in the n-3 LCPUFA group (34/368 (9%) v 52/338 (15%);
unadjusted relative risk 0.61, 0.40 to 0.91, P=0.02; adjusted relative risk
0.62, 0.41 to 0.93, P=0.02), but no difference between groups in
immunoglobulin E associated food allergy was seen.
Conclusion n-3 LCPUFA supplementation in pregnancy did not reduce
the overall incidence of immunoglobulin E associated allergies in the
first year of life, although atopic eczema and egg sensitisation were
lower. Longer term follow-up is needed to determine if supplementation
has an effect on respiratory allergic diseases and aeroallergen
sensitisation in childhood.
Trial registration Australian New Zealand Clinical Trials Registry
ACTRN12610000735055 (DOMInO trial: ACTRN12605000569606).
Introduction
The prevalence of allergic diseases in Australia and other
industrialisedcountrieshasincreasedoverthepast30yearsand
is now estimated to be at least 20%.
1-3 The cost to healthcare
systems and the burden to families are high.
4 5 The pattern of
allergic disease differs with age; the incidence of food allergy
and atopic dermatitis peaks by 1 year of age, whereas asthma
and allergic rhinitis continue to rise until around 15 years of
age.
6 The increase in allergic disease has occurred too rapidly
(withinonetotwogenerations)tobearesultofgeneticchanges
in the population, so it is likely to be related to environmental
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Research
RESEARCHchanges. In this context, strategies to reduce the burden of
disease through prevention will be of enormous importance.
The period of increase in allergic diseases has coincided with
a substantial shift in dietary intake of fatty acids to favour n-6
(omega 6) fatty acids over n-3 (omega 3) fatty acids, leading to
speculation that the change in dietary fatty acid balance may be
linked to the increased prevalence of childhood allergic
disease.
7 8 Diets rich in n-6 fatty acids, through increased
consumption of vegetable oils rich in linoleic acid (18:2n-6),
leadtoapredominanceofarachidonicacid(20:4n-6)intissues.
Arachidonicacidgivesrisetoeicosanoidssuchasprostaglandin
E2,whichcanenhancethesynthesisofThelpertype2cytokines
and immunoglobulin E antibodies—the hallmark of atopic
responses to allergens. When diets are high in n-3 long chain
polyunsaturated fatty acids (LCPUFA) (for example in fish),
these are readily incorporated into cellular phospholipids,
displacingarachidonicacidintheprocess.Thisleadstoarange
ofbiochemicalandimmunologicalchanges,includingreduction
of prostaglandin E2 synthesis, alteration of receptor expression
and activity, and reduced pro-inflammatory cytokine
responses.
9 10 Plausible mechanisms thus exist by which diets
high in n-3 LCPUFA may modulate the development of
immunoglobulin E mediated allergic disease and regulate
immune responses.
Two previous randomised trials have shown that fish oil
treatment during pregnancy, compared with placebo, resulted
in down regulation of cytokine responses (interleukin-5,
interleukin-13, interferon-γ) to allergens in mononuclear cells
in cord blood,
11 12 as well as up regulation of transforming
growth factor-β in cord blood.
12 These data are supported by a
recent Swedish study showing fewer infants with
immunoglobulin E associated eczema in response to n-3
LCPUFA supplementation from the 25th week of gestation
(4/52 (8%) v 15/63 (24%), P<0.05).
13 However, the lack of
clarity regarding randomisation processes in this study means
that one cannot exclude the possibility of bias, and the small
samplesizemeansthatalargedegreeofuncertaintyisassociated
withtheresults,highlightingtheneedforlarger,moredefinitive
randomisedtrials.Wedesignedourstudytodeterminetheeffect
of n-3 LCPUFA supplementation during pregnancy on
immunoglobulinEassociatedallergies(eczemaorfoodallergy)
at 12 months of age in infants with high hereditary risk. We
recruited participants from the Docosahexaenoic Acid to
Optimise Mother Infant Outcome (DOMInO) trial, which is a
double blind, multicentre, randomised controlled trial of n-3
LCPUFAsupplementation,predominantlyasdocosahexaenoic
acid,inpregnancytoevaluatesymptomsofmaternaldepression
and neurodevelopment of young children.
14 We have already
shown that n-3 LCPUFA supplementation did not change the
prevalence of maternal postnatal depression and that the mean
developmental scores of children did not differ at 18 months of
age.
14
Methods
Study design
Pregnantwomenwereapproachedtoentertheallergyfollow-up
after randomisation into the DOMInO trial.
14 Briefly, women
were randomly allocated a unique number that corresponded to
treatment or control through a computer driven telephone
randomisationserviceaccordingtoanindependentlygenerated
randomisation schedule, with balanced variable sized blocks.
Stratification was by centre and parity (first birth versus
subsequent births). Women were eligible for the allergy
follow-up if the unborn baby had a mother, father, or sibling
with a history of any medically diagnosed allergic disease
(asthma, allergic rhinitis, eczema) and they were enrolled from
the Women’s and Children’s Hospital or Flinders Medical
Centre in Adelaide. Only Adelaide based families participated
in the allergy follow-up because this allowed optimal quality
assurance for allergy testing and achievement of an adequate
sample size was possible. Eligible women were given
information about the allergy follow-up, and written informed
consent was sought before delivery. Baseline characteristics,
including maternal age, maternal smoking during pregnancy,
and parental education, were recorded.
Dietary treatments
The dietary treatments for the DOMInO trial have been
described previously.
14 Briefly, women allocated to the n-3
LCPUFA group were asked to consume three 500 mg capsules
of fish oil concentrate rich in docosahexaenoic acid daily,
providing 800 mg of docosahexaenoic acid and 100 mg of
eicosapentaenoic acid (20:5n-3; Incromega 500 TG, Croda
Chemicals, East Yorkshire, UK); women in the control group
were asked to take three 500 mg vegetable oil capsules without
n-3 LCPUFA daily. Women took capsules from 21 weeks’
gestation until delivery. The vegetable oil capsules contained a
blend of three non-genetically modified oils (rapeseed,
sunflower,andpalm)inequalproportions,whichwasdesigned
to match the polyunsaturated, monounsaturated, and saturated
fatty acid profile of the average Australian diet.
15 All capsules
were similar in size, shape, and colour and were donated by
Efamol, Surrey, UK. Neither the women nor the research staff
were aware of the treatment allocated. Women reported their
adherence to supplementation at telephone calls at 28 and 36
weeks’ gestation. In addition, the concentration of individual
LCPUFAinplasmaphospholipidsfromcordbloodwasassessed
as an independent biomarker of adherence.
Infant allergic disease outcome assessments
The primary outcome for the nested allergy follow-up at 1 year
of age was diagnosis of immunoglobulin E associated allergic
disease (eczema or food allergy with sensitisation). One of five
medical practitioners (blinded to treatment group allocation)
made the diagnosis by taking a structured history and doing a
standardised clinical examination, and one of four experienced
nursesdidskinpricktests.Themedicalpractitionersandnurses
werespecificallytrainedinthetrialassessmentsandhadquality
assurancereviewseverysixmonthswithoneoftheinvestigators
(DJP).
We defined sensitisation as a positive skin prick test to at least
oneoftheallergensassessed.Weconsideredatesttobepositive
if the mean of the horizontal and perpendicular weal diameters
was 3 mm or greater in size than that of the negative control
site at 15 minutes. The allergens tested were cows’ milk, whole
hens’egg,wheat,tuna,peanut,grasspollen,perennialryegrass,
olivetreepollen,Alternariatenuis,cathair,andhousedustmite
(Dermatophagoidespteronyssinus).Glycerinandhistamine(10
mg/mL) were used as negative and positive controls.
Wedefinedeczemaasthepresenceofeczema(criteriaaccording
to Hanifin and Rijka
16) on medical review or a history of an
itchy rash distributed to the facial, flexural, or extensor surface
of the skin that had followed a fluctuating or chronic course.
We defined immunoglobulin E associated eczema or atopic
eczema as eczema with sensitisation, in which the infant had a
positive skin prick test to at least one of the allergens assessed.
We defined immunoglobulin E associated food allergy as a
historyofimmediate(within60minutes)skinrash(hives,rash,
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RESEARCHor swelling) with or without respiratory symptoms (cough,
wheeze, stridor), gastrointestinal symptoms (abdominal pain,
vomiting, loose stools), or cardiovascular symptoms (collapse)
followingingestionofafood(suchasegg,peanut)andapositive
skin prick test to the implicated food.
When the infants were 6 months of age, a research nurse or
research assistant telephoned parents and asked them a set of
standard questions to prospectively monitor symptoms of
allergic disease, and these data sheets were available to the
medicalpractitionerstofacilitatetheir1yearofageassessments.
Thesephonecallsalsoprovidedanopportunitytoupdatefamily
contact details to maximise follow-up and collect information
on possible confounding variables at both 6 and 12 months of
age, including details of infant feeding and rejection of foods,
use of antibiotics, number of other children in the home, and
presence of a dog or cat as a pet. Other possible confounding
variables such as mode of delivery were available from the
DOMInO trial dataset.
Sample size and statistical analysis
We calculated the sample size for the allergy follow-up by
assuming an incidence of atopic eczema or food allergy in high
risk Australian infants at 1 year of age of 14%.
11 With 328
children in each treatment group, we would be able to detect an
absolute reduction of 7% (relative reduction of 50%) in the
incidence of atopic eczema or food allergy from 14% to 7%
with 80% power (α=0.05). Both parents and the healthcare
sector consider such a reduction to be important, and it was
realistic compared with the 67% and 59% relative reductions
inchildallergyoutcomesinresponsetofishoiltreatmentduring
pregnancy reported by Furuhjelm et al and Olsen et al.
13 17
We did all analyses according to the intention to treat principle.
We used multiple imputations to deal with missing data (both
outcomes and covariates), with 50 complete datasets imputed
for analysis. We imputed data and combined results by using
the mi and mi_analyze procedures in SAS version 9.2. We did
imputationsequentially(baselinevariables,post-randomisation
variables,outcomes)byusingtheparametricregressionmethod
for continuous and count variables and the logistic regression
method for binary and ordinal variables.
18 In addition to a
primary imputed analysis, we did sensitivity analyses on the
original data and on imputed data created using different seeds
and different imputation models. All approaches produced
similar results, so we present only the results of the primary
imputed analysis here. Web appendix A gives further details of
the imputation approach, the amount of missing data, and the
results of sensitivity analyses.
We used linear regression models to analyse continuous
outcomes,withtreatmenteffectsexpressedasmeandifferences.
We used negative binomial regression models to analyse count
outcomes, with the effect of treatment expressed as a ratio of
means. We analysed binary outcomes by using log binomial
regression models, with treatment effects expressed as relative
risks.WeanalysedrarebinaryoutcomesbydoingFisher’sexact
tests on the original (unimputed) data. We did both unadjusted
and adjusted analyses, with adjustment for the stratification
variables of centre and parity as well as the pre-specified
baseline variables of infant sex and maternal history of allergic
disease. We considered the adjusted analyses to be the primary
analyses.
We also compared potential confounding variables measured
after randomisation between groups. We used Fisher’s exact
tests and Wilcoxon tests based on the original unimputed data
to assess binary and continuous confounders respectively. We
assessed statistical significance at the two sided P<0.05 level.
We used SAS version 9.2 for all analyses.
Results
The figure⇓ shows the study profile. Enrolment for the allergy
follow-up began on 20 March 2006 and ended on 8 May 2008.
We enrolled 234/368 (64%) of the n-3 LCPUFA
supplementationgroupand216/338(64%)ofthecontrolgroup
from the Women’s and Children’s Hospital. Data collection at
1 year of age was completed on 26 August 2009. In total,
681/706 (96.5%) infants attended their 1 year medical review
and 666/706 (94.3%) had skin prick tests results. The baseline
demographic and clinical characteristics of the participating
infants were comparable between the two groups (table 1⇓).
Concentrations of docosahexaenoic acid and eicosapentaenoic
acid in the plasma phospholipids of cord blood from women in
the n-3 LCPUFA group were greater than those for the control
group (docosahexaenoic acid: median 7.5% v 6.2% total
phospholipid fatty acids, P<0.001; eicosapentaenoic acid:
median 0.54% v 0.27% total phospholipid fatty acids, P<0.001
based on a comparison of mean log transformed values). The
concentrationoftotaln-3LCPUFAinthecordbloodwashigher
inwomeninthen-3LCPUFAgroup(median8.8%v7.2%total
phospholipid fatty acids, P<0.001 based on a comparison of
mean log transformed values), whereas the concentration of
arachidonic acid in cord blood was lower in women in the n-3
LCPUFA group compared with control (mean 14.6% v 16.4%,
P<0.001 based on a comparison of means). At 28 weeks’
gestation,284/368(77%)ofmothersinthen-3LCPUFAgroup
and 270/338 (80%) of mothers in the control group reported
that they had missed zero to three capsules a week (from a total
of21capsulesaweek).Fewerthan2%ofmothersineachgroup
chose not to take any capsules.
Infant allergic disease outcomes
We found no difference in the overall percentage of infants
diagnosed as having immunoglobulin E associated allergic
disease (eczema or food allergy with sensitisation) at 1 year of
agebetweenthen-3LCPUFAandcontrolgroups(32/368(9%)
v 43/338 (13%); unadjusted relative risk 0.68, 95% confidence
interval 0.43 to 1.05, P=0.08; adjusted relative risk 0.70, 0.45
to 1.09, P=0.12) (table 2⇓). However, the percentage of infants
with atopic eczema at 1 year of age was lower in the n-3
LCPUFA group than in the control group, whereas the
percentage of infants with food allergy did not differ between
groups (table 2⇓). The incidence of food allergy was about 3%,
and most food allergies were to egg (13/706 (1.8%)—6/368
(1.6%) in the n-3 LCPUFA group and 7/338 (2.1%) in the
control group; unadjusted relative risk 0.78, 0.26 to 2.29,
P=0.65; adjusted relative risk 0.79, 0.27 to 2.30, P=0.66). The
percentage of infants with non-immunoglobulin E associated
allergic disease (without sensitisation) did not differ between
groups (table 2⇓). Web appendix B shows other infant allergic
disease outcomes not presented in table 2⇓ but analysed
according to the statistical analysis plan. Respiratory
manifestations of allergic disease were rare and did not differ
between groups (web appendix B).
Infants were most commonly sensitised to egg (12.2% of all
infants). The percentage of infants introduced to egg by 1 year
of age was 86% (315/368) in the n-3 LCPUFA group and 86%
(292/338) in the control group. More infants were sensitised to
egg in the control group than in the n-3 LCPUFA group (table
2⇓), and we detected more infants in the control group who
repeatedly spat out or refused to eat egg (18/338 (5%) v 9/368
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RESEARCH(2%), P=0.06) (web appendix B). The overall rate of
sensitisation to peanut was 5.2% and did not differ between
groups (table 2⇓). The frequency of sensitisation to all other
allergens tested was less than 2% (tables 2⇓ and 3⇓).
Other infant clinical outcomes
No anaphylactic reactions were reported. The percentage of
infants with any hospital admissions during the first year of life
(67/368 (18%) in n-3 LCPUFA group versus 74/338 (22%) in
the control group; unadjusted relative risk 0.82, 0.61 to 1.11,
P=0.20; adjusted relative risk 0.82, 0.61 to 1.11, P=0.20) and
the total number of hospital admissions per child (mean 0.25 in
the n-3 LCPUFA group versus 0.35 in the control group;
unadjusted ratio of means 0.72, 0.50 to 1.03, P=0.08; adjusted
ratioofmeans0.73,0.51to1.04,P=0.08)didnotdifferbetween
groups. Similarly, we found no differences between the groups
for the number of infants visiting a doctor because they were
unwell (336/368 (91%) in the n-3 LCPUFA group versus
310/338 (92%) in the control group; unadjusted relative risk
1.00, 0.95 to 1.04, P=0.89; adjusted relative risk 1.0, 0.95 to
1.04,P=0.85)orthenumberofvisitstoadoctorperchild(mean
4.55inthen-3LCPUFAgroupversus4.28inthecontrolgroup;
unadjusted ratio of means 1.06, 0.93 to 1.22, P=0.38; adjusted
ratio of means 1.06, 0.93 to 1.22, P=0.38). The percentage of
infants with respiratory tract infections (65/368 (18%) in the
n-3 LCPUFA group versus 66/338 (20%) in the control group;
unadjusted relative risk 0.90, 0.66 to 1.23, P=0.50; adjusted
relative risk 0.91, 0.67 to 1.23, P=0.53) did not differ between
groups.Wealsofoundnodifferencebetweenthegroupsforthe
number of infants exposed to antibiotic treatment during the
first12monthsoflife(214/368(58%)inthen-3LCPUFAgroup
versus 190/338 (56%) in the control group; unadjusted relative
risk 1.03, 0.91 to 1.18, P=0.61; adjusted relative risk 1.04, 0.91
to 1.18, P=0.55). Ear infections were the most common reason
for antibiotic use in infancy (99/368 (27%) in the n-3 LCPUFA
group versus 84/338 (25%) in the control group; unadjusted
relative risk 1.08, 0.84 to 1.39, P=0.53; adjusted relative risk
1.10, 0.86 to 1.41, P=0.44).
Possible confounding variables
Table4⇓showscharacteristicsofinfantfeedingmeasuredafter
randomisation. More infants in the n-3 LCPUFA group than in
thecontrolgroupwereinitiallybreastfed,whereasmoreinfants
in the control group than the n-3 LCPUFA group were given
cows’ milk protein formula in the first six months of life (table
4
4). We found no differences between the groups for other
possible confounding variables that may influence allergic
disease, including the number of infants born by caesarean
delivery (104/368 (28%) in the n-3 LCPUFA group compared
with 98/338 (29%) in the control group, P=0.83), the age when
eggswereintroduced(median8.0(interquartilerange6.0-10.0)
months for both groups, P=0.42), the age when fish was
introduced (median 9.0 (7.0-10.0) months for both groups,
P=0.90), the age when nuts were introduced (median 10.0
(8.0-11.0)monthsforbothgroups,P=0.65),thenumberofother
children in the home (median 1.0 for both groups, P=0.56), and
havingacatordogasapet(241/366(66%)inthen-3LCPUFA
group compared with 208/334 (62%) in the control group,
P=0.33).
Discussion
Our study showed that a prenatal dose of 900 mg/day of n-3
LCPUFA had no effect on the composite outcome of
immunoglobulin E associated allergic disease, comprising
eczema or food allergy, in the first year of life. However,
treatment with n-3 LCPUFA during pregnancy reduced the
percentage of infants with atopic eczema and reduced the
percentage of infants with sensitisation to eggs. We did not
detect any effect of n-3 LCPUFA supplementation during
pregnancy on allergic disease without sensitisation (that is,
non-immunoglobulin E associated allergy).
Comparison with other studies
Our observations that infants exposed to n-3 LCPUFA during
pregnancy were less likely to develop atopic eczema and had a
lower propensity for sensitisation are consistent with the
postulate that the immunomodulatory effects of n-3 LCPUFA
are mediated through mechanisms associated with the atopic
(immunoglobulin E associated) responses.
8-10 Additionally, our
finding that fewer infants in the n-3 LCPUFA group were
sensitised to egg compared with control is consistent with the
findings of previous smaller trials by Dunstan et al and
Furuhjelm et al.
11 13 As many children with egg allergy are
known to develop asthma and allergic respiratory disease,
19
longer term follow-up of the children in our study is important
to determine whether the lower rates of egg sensitisation in the
n-3LCPUFAgrouptranslatetoloweraeroallergensensitisation
and fewer children with respiratory allergic diseases at a later
time. Of interest are the findings by Olsen et al,
17 who showed
that n-3 LCPUFA supplementation during pregnancy reduced
asthma in adolescence. However, the allergy outcomes from
this trial were obtained through linkage to a national registry of
doctors’ visits.
17 The expected event rates in Olsen et al were
low, and whether diagnoses were made according to standard
definitions is not known.
17 The planned allergy assessments of
thechildreninourstudyat3and6yearsofagewillbeimportant
in documenting the progression of allergic disease and whether
n-3 LCPUFA supplementation during pregnancy has long term
effects.
Strengths and limitations
Strengths of our study are the concealed randomisation, the
largesamplesize,andtheminimalrateofattrition.Furthermore,
women included in our trial had comparable demographic
characteristics to Australian women who gave birth in
2006-7,
20 21suggestinggeneralisabilityoftheresultstothewider
population.
Alimitationofthestudyisthatweusedaconservativedefinition
to define food allergy. Infants were diagnosed as having food
allergy only if they were sensitised and had a clear clinical
history of an immediate allergic reaction to the offending food.
We did not have resources to do oral food challenges for the
infantswithsuspectedfoodallergy(sensitisationtotheoffending
food and a history of repeatedly spitting out or refusing to eat
this food), and we may have underestimated the true frequency
of food allergy, as may be demonstrated with egg allergy.
Although only about 2% of infants had confirmed egg allergy
in our trial (1.6% in the n-3 LCPUFA group and 2.1% in the
control group), a further 4% (2.4% in the n-3 LCPUFA group
and 5.3% in the control group) had a suspected egg allergy. A
recent Australian cohort study estimated the prevalence of egg
allergy to be 8.9% at 1 year of age on the basis of challenge
with raw egg,
22 which approximates the total confirmed and
suspected egg allergy in our control group (7.4% v 4.1% in the
n-3 LCPUFA group; web appendix B).
Another potential limitation of our study was the observation
that the initiation of breast feeding and the use of cows’ milk
protein formula in the first six months differed between the
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notadjustfortheminthestatisticalanalyses;however,wefound
no relation between the initiation of breast feeding and atopic
eczema or between breast feeding and egg sensitisation in
exploratory analyses. Furthermore, very few infants (total of
9/706; 6/368 (2%) in the n-3 LCPUFA group and 3/338 (1%)
in the control group) in this study were sensitised to cows’ milk
protein, despite more infants in the control group having been
fed cows’ milk based formula in the first six months of life.
Three quarters of the infants in our trial had been exposed to
cows’ milk based formula before 6 months of age, and 99% of
infantshadbeenintroducedtocows’milkby12monthsofage.
Collectively, these data suggest that the small imbalance
between groups for breast feeding and formula feeding in the
first 6 months of life did not influence the outcomes of the trial.
Conclusions and policy implications
Many of the commercially available prenatal supplements
provide low doses of n-3 LCPUFA (<300 mg/day compared
with the 900 mg/day used in our trial) on the basis of consensus
guidelines and recommendations that have largely focused on
improvingoutcomesofpregnancyandenhancingdevelopmental
outcomes in early childhood.
23 24 However, from an
immunological standpoint, the doses available in many
commercial supplements are unlikely to suppress the
concentration of arachidonic acid in cord blood
25; they are
thereforeunlikelytoresultinthechangesinprostaglandinsand
cytokines associated with higher dose n-3 LCPUFA
supplementation.
26-28Evenwiththehigherdosesupplementation
used in our study, we did not show an overall reduction in
immunoglobulin E associated allergic disease at 1 year of age,
although our data suggest that infant atopic eczema and
sensitisation to egg are reduced by n-3 LCPUFA
supplementation during pregnancy. Clearly, further follow-up
studies are needed to definitively determine whether prenatal
n-3 LCPUFA supplementation is beneficial as an allergy
prevention strategy.
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RESEARCHWhat is already known on this topic
The prevalence of allergic diseases in industrialised countries is estimated to be at least 20%
The period of increase in allergic diseases has coincided with a substantial shift in dietary intake of fatty acids to favour n-6 fatty acids
over n-3 fatty acids
Several mechanistic studies have suggested that higher intakes of n-3 long chain polyunsaturated fatty acids (LCPUFA) during pregnancy
modulate the neonatal immune response
What this study adds
n-3 LCPUFA supplementation in pregnancy did not reduce the overall incidence of immunoglobulin E associated allergies in the first
year of life, although atopic eczema and egg sensitisation were lower
Longer term follow-up of these children will determine the effectiveness of n-3 LCPUFA supplementation in pregnancy as a preventive
strategy for allergic diseases
This is an open-access article distributed under the terms of the Creative Commons
Attribution Non-commercial License, which permits use, distribution, and reproduction in
any medium, provided the original work is properly cited, the use is non commercial and
is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-
nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
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RESEARCHTables
Table 1| Baseline demographic and clinical characteristics. Values are numbers (percentages) unless stated otherwise
Control (n=338) n-3 LCPUFA (n=368) Characteristic
29.5 (5.6) 29.6 (5.7) Mean (SD) mother’s age at trial entry (years)
131 (39) 150 (41) Parity zero
45 (13) 47 (13) Maternal smoking during pregnancy
222 (66) 232 (63) Mother completed secondary education
182 (54) 196 (53) Father completed secondary education
236 (70) 257 (70) Maternal history of allergic disease:
63 (19) 92 (25) Eczema
148 (44) 156 (42) Asthma
121 (36) 133 (36) Allergic rhinitis
178 (53) 207 (56) Paternal history of allergic disease:
37 (11) 53 (14) Eczema
86 (25) 122 (33) Asthma
109 (32) 108 (29) Allergic rhinitis
97 (29) 109 (30) Both parents with history of allergic disease
168 (50) 169 (46) Infant’s sex male
LCPUFA=long chain polyunsaturated fatty acid.
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RESEARCHTable 2| Clinical allergy assessment outcomes at 12 months of age.
Adjusted† P
value
Adjusted† relative risk
(95% CI)
Unadjusted P
value
Unadjusted relative risk
(95% CI) Control* (n=338)
n-3 LCPUFA*
(n=368) Outcome
0.12 0.70 (0.45 to 1.09) 0.08 0.68 (0.43 to 1.05) 43 (13) 32 (9) Allergic disease with
sensitisation:
0.06 0.64 (0.40 to 1.03) 0.04 0.61 (0.38 to 0.98) 39 (12) 26 (7) Eczema with sensitisation
0.93 0.96 (0.41 to 2.25) 0.88 0.94 (0.40 to 2.22) 11 (3) 11 (3) Food allergy with
sensitisation
0.08 0.75 (0.53 to 1.04) 0.07 0.73 (0.52 to 1.02) 67 (20) 53 (14) Sensitisation with/without
allergic disease:
0.02 0.62 (0.41 to 0.93) 0.02 0.61 (0.40 to 0.91) 52 (15) 34 (9) Egg sensitisation
0.16 0.63 (0.34 to 1.19) 0.15 0.62 (0.33 to 1.18) 22 (7) 15 (4) Peanut sensitisation
0.51 3 (1) 6 (2) Cows’ milk sensitisation‡
0.57 1.10 (0.79 to 1.55) 0.57 1.10 (0.79 to 1.55) 53 (16) 63 (17) Allergic disease without
sensitisation
LCPUFA=long chain polyunsaturated fatty acid.
*All data are based on analysis of 50 imputed datasets; values are numbers (percentages).
†Adjusted for centre, parity, maternal history, and sex.
‡Fisher’s exact test using original data; adjusted/imputed analyses not done owing to rarity of outcomes (n-3 LCPUFA group, n=349; control group, n=317).
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RESEARCHTable 3| Sensitisation to other allergen skin prick test extracts. Values are numbers (percentages) unless stated otherwise
P value* Control (n=317) n-3 LCPUFA (n=349) Extract
>0.99 2 (0.6) 2 (0.6) Wheat
0.25 0 (0.0) 3 (0.9) Fish
>0.99 1 (0.3) 1 (0.3) Ryegrass pollen
NA 0 (0.0) 0 (0.0) Olive tree pollen
>0.99 1 (0.3) 1 (0.3) Dermatophagoides pteronyssinus
0.78 5 (1.6) 7 (2.0) Cat hair
0.38 1 (0.3) 4 (1.2) Alternaria tenuis
LCPUFA=long chain polyunsaturated fatty acid; NA=not applicable.
*Fisher’s exact test using original data; adjusted/imputed analyses not done owing to rarity of outcomes.
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RESEARCHTable 4| Infant feeding related post-randomisation characteristics. Values are numbers (percentages) unless stated otherwise
P value* Control n-3 LCPUFA Characteristic
0.005 303/333 (91) 348/362 (96) Initiation of breast feeding
0.29 144/333 (43) 171/362 (47) Any breast feeding at 6 months of age
0.17 307/334 (92) 326/367 (89) Ever fed formula
0.76 1.0 (0.0-4.0) 1.0 (0.0-4.0) Median (interquartile range) age formula introduced (months)
0.02 265/332 (80) 260/361 (72) Use of cows’ milk protein formula in first 6 months
0.61 8/332 (2) 11/361 (3) Use of hydrolysed protein formula in first 6 months
0.053 5.0 (4.0-5.0) 5.0 (4.0-5.0) Median (interquartile range) age solids introduced (months)
LCPUFA=long chain polyunsaturated fatty acid.
*Groups compared using Fisher’s exact tests for binary outcomes and Wilcoxon tests for continuous outcomes.
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RESEARCHFigure
Flow diagram of trial. DOMInO=Docosahexaenoic Acid to Optimise Mother Infant Outcome; LCPUFA=long chain
polyunsaturated fatty acids. *Death was stillbirth and unrelated to objective of study
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